Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease
2006

Matrix Metalloproteinases and Kidney Disease

Sample size: 12 publication 10 minutes Evidence: high

Author Information

Author(s): Michael Zeisberg, Mona Khurana, Velidi H Rao, Dominic Cosgrove, Jean-Philippe Rougier, Michelle C Werner, Charles F Shield III, Zena Werb, Raghu Kalluri

Primary Institution: Beth Israel Deaconess Medical Center and Harvard Medical School

Hypothesis

MMPs with overlapping substrate specificities could compensate for each other's absence in the setting of GBM-degradation.

Conclusion

Preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection.

Supporting Evidence

  • Increased MMP expression was observed in kidneys from patients with end-stage renal failure due to X-linked Alport syndrome.
  • Pharmacological ablation of MMP activity before the onset of proteinuria led to significant attenuation in disease progression.
  • Inhibition of MMPs after the onset of proteinuria accelerated disease progression.

Takeaway

This study shows that certain enzymes can help or hurt kidney health, depending on when they are blocked. Blocking them early can help, but blocking them later can make things worse.

Methodology

The study used a mouse model of Alport syndrome and human kidney samples to evaluate the role of MMPs in kidney disease progression.

Limitations

The study primarily focused on a mouse model, which may not fully replicate human disease.

Participant Demographics

The study included male patients with X-linked Alport syndrome and age-matched control mice.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pmed.0030100

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication